1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Gao Q, Shi Y, Wang X, Zhou J, Qiu S and
Fan J: Translational medicine in hepatocellular carcinoma. Front
Med. 6:122–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pervaiz S and Holme AL: Resveratrol: Its
biologic targets and functional activity. Antioxid Redox Signal.
11:2851–2897. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Foti Cuzzola V, Ciurleo R, Giacoppo S,
Marino S and Bramanti P: Role of resveratrol and its analogues in
the treatment of neurodegenerative diseases: Focus on recent
discoveries. CNS Neurol Disord Drug Targets. 10:849–862. 2011.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Zordoky BN, Robertson IM and Dyck JR:
Preclinical and clinical evidence for the role of resveratrol in
the treatment of cardiovascular diseases. Biochim Biophys Acta.
1852:1155–1177. 2015. View Article : Google Scholar
|
6
|
Signorelli P and Ghidoni R: Resveratrol as
an anticancer nutrient: Molecular basis, open questions and
promises. J Nutr Biochem. 16:449–466. 2005. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wood JG, Rogina B, Lavu S, Howitz K,
Helfand SL, Tatar M and Sinclair D: Sirtuin activators mimic
caloric restriction and delay ageing in metazoans. Nature.
430:686–689. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Delmas D, Jannin B, Cherkaoui Malki M and
Latruffe N: Inhibitory effect of resveratrol on the proliferation
of human and rat hepatic derived cell lines. Oncol Rep. 7:847–852.
2000.PubMed/NCBI
|
9
|
Parekh P, Motiwale L, Naik N and Rao KV:
Downregulation of cyclin D1 is associated with decreased levels of
p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of
resveratrol in liver cancer cells. Exp Toxicol Pathol. 63:167–173.
2011. View Article : Google Scholar
|
10
|
Weng SC, Kashida Y, Kulp SK, Wang D,
Brueggemeier RW, Shapiro CL and Chen CS: Sensitizing estrogen
receptor-negative breast cancer cells to tamoxifen with OSU-03012,
a novel celecoxib-derived phosphoinositide-dependent protein
kinase-1/Akt signaling inhibitor. Mol Cancer Ther. 7:800–808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Khan A, Aljarbou AN, Aldebasi YH, Faisal
SM and Khan MA: Resveratrol suppresses the proliferation of breast
cancer cells by inhibiting fatty acid synthase signaling pathway.
Cancer Epidemiol. 38:765–772. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nho RS and Hergert P: FoxO3a and disease
progression. World J Biol Chem. 5:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu
HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol Protects PC12
cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a
pathway. Cell Mol Neurobiol. 35:513–522. 2015. View Article : Google Scholar
|
14
|
Polter A, Yang S, Zmijewska AA, van Groen
T, Paik JH, Depinho RA, Peng SL, Jope RS and Li X: Forkhead box,
class O transcription factors in brain: Regulation and behavioral
manifestation. Biol Psychiatry. 65:150–159. 2009. View Article : Google Scholar :
|
15
|
Su JL, Cheng X, Yamaguchi H, Chang YW, Hou
CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, et al:
FOXO3a-dependent mechanism of E1A-Induced chemosensitization.
Cancer Res. 71:6878–6887. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wang JG, Zheng XX, Zeng GY, Zhou YJ and
Yuan H: Purified vitexin compound 1 induces apoptosis through
activation of FOXO3a in hepatocellular carcinoma. Oncol Rep.
31:488–496. 2014.
|
17
|
Carbajo-Pescador S, Steinmetz C, Kashyap
A, Lorenz S, Mauriz JL, Heise M, Galle PR, González-Gallego J and
Strand S: Melatonin induces transcriptional regulation of Bim by
FoxO3a in HepG2 cells. Br J Cancer. 108:442–449. 2013. View Article : Google Scholar :
|
18
|
He L, Yang X, Cao X, Liu F, Quan M and Cao
J: Casticin induces growth suppression and cell cycle arrest
through activation of FOXO3a in hepatocellular carcinoma. Oncol
Rep. 29:103–108. 2013.
|
19
|
Izzotti A: Molecular medicine and the
development of cancer chemopreventive agents. Ann N Y Acad Sci.
1259:26–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Pirola L and Fröjdö S: Resveratrol: One
molecule, many targets. IUBMB Life. 60:323–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Tzivion G, Dobson M and Ramakrishnan G:
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins.
Biochim Biophys Acta. 1813:1938–1945. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Hong ZY, Lee HJ, Shin DY, Kim SK, Seo M
and Lee EJ: Inhibition of Akt/FOXO3a signaling by constitutively
active FOXO3a suppresses growth of follicular thyroid cancer cell
lines. Cancer Lett. 314:34–40. 2012. View Article : Google Scholar
|
23
|
Roy SK, Chen Q, Fu J, Shankar S and
Srivastava RK: Resveratrol inhibits growth of orthotopic pancreatic
tumors through activation of FOXO transcription factors. PLoS One.
6:e251662011. View Article : Google Scholar : PubMed/NCBI
|